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likely explains why older patients in this cohort predomi-
nantly had aggressive disease. Not having clear answers of
who will beneﬁt, we generally adopt a shared decision-
making process, involving physicians, patients, and patient
families. An interesting attempt to gain expert physician
guidance on the role of alloHCT in follicular lymphoma [9]
identiﬁed some areas of consensus, others of disagreement.
Relatively unexplored is decision-making from the patient
perspective, although there are some studies in the pediatric
population [10]. My anecdotal observations are that oncolo-
gists often focus on potential beneﬁts, whereas patients often
focus on risks of toxicity and especially mortality, particularly
if they have had prior autoSCT. It would be worth learning
more about decision-making from the patient standpoint to
better assist in the process.
This report byMcClune et al. [1] continues the long history
of CIBMTR contributions to the literature that help guide the
wide range of the decisions involved in stem cell trans-
plantation. Utility of these data in daily practice would be
strengthened by streamlining the analytic process so that
patients undergoing alloHCT more recently than 2007 are
included, as well as comparing outcomes with those in the
non-HCT populations adjusted for comorbidities, perhaps
adapting the HCT-CI to the nonestem cell transplantation
group or using comprehensive geriatric assessments. Mean-
while, recent advances in targeted therapies approved for
indolent and mantle cell lymphoma are already altering the
equation, and we anticipate similar advances for aggressive
lymphomas. Although reasonable people may have different
deﬁnitions of “encouraging,” these data do support the idea
that age alone should not be a deciding factor in alloSCT.Financial disclosure: See Acknowledgments on page 907.
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Milano et al. report a lack of evidence for cord colitis syn-
drome (CCS) after umbilical cord blood transplantation
(UCBT), instead positing acute graft-versus-host disease
(GVHD) as the source [1]. CCS was initially described as a
syndrome of noninfectious, antibiotic-responsive diarrhea
after UCBT [2]. The case deﬁnition of CCS required histo-
pathologic examination of endoscopic tissue that excluded
GVHD and other etiologies of diarrhea. Biopsies alsodemonstrated presence of chronic inﬂammation, deﬁned as
basal plasmacytosis, paneth cell metaplasia, architectural
distortion, and granulomas.
In the initial publication by Herrera et al. [2], patients
treated at the DanaeFarber Cancer Institute/Brigham and
Women’s Hospital Hematopoietic Stem Cell Transplantation
Service presented with severe diarrheal illness, fever, and
weight loss, and many required hospitalization. The cases
occurred late (median, 131 days) and rarely had antecedent
GVHD of the gut. Perhaps the most striking ﬁnding was that
all patients responded to metronidazole  ﬂoroquinalone.
One-half developed recurrent diarrhea upon cessation of an-
tibiotics, but all recaptured their response following reinsti-
tution. The histological features differed from classic acute
GVHD with a paucity of crypt apoptosis and evidence of
chronic inﬂammation, namely paneth cell metaplasia and
granulomas.
Several explanations for CCS have been proposed and
include delayed GVHD, Tropheryma whipplei infection,
transfusion-related acute gut injury (TRAGI), and a chronic
interferon-g response against the nondominant cord unit [3-
6]. More recently, shotgun DNA sequencing performed on
archived tissues from 2 patients with cord colitis revealed a
J. Magenau, P. Reddy / Biol Blood Marrow Transplant 20 (2014) 905e907 907profound lack of bacterial diversity and sequences with ho-
mology to Bradyrhizobium genus (provisionally termed
Bradyrhizobium enterica) [7]. Moreover, samples taken after
antibiotic therapy had signiﬁcantly reduced B. enterica se-
quences. Recently, 16S rDNA-based microbial community
proﬁling identiﬁed outgrowth of enterotoxin-producing
Bacteroides fragilis in a patient with CCS, but not B. enterica
[8]. In yet another study, Shimoji et al. reported chronic
active colitis with granulomatous inﬂammation and paneth
cell metaplasia. They suggest it is not speciﬁc to CCS and was
associated with GVHD and cytomegalovirus colitis[9]. How-
ever, this study differs from the initial report in certain
important aspects; namely, biopsies were obtained earlier
(median, 50 days) and most patients did not receive UCBT.
In this issue, Milano et al. sought to validate CCS by
reviewing colonic biopsies after UCBT for chronic colitis,
granulomatous change, and paneth cell metaplasia, for pa-
tients treated in Seattle. The indications for biopsy were late
gastrointestinal symptoms, including watery diarrhea.
Although chronic active colitis was common, the putative
hallmarks of CCS, namely paneth cell metaplasia and granu-
lomas, were rarely appreciated. In contrast, more than one
half of specimens had apoptotic cells, frequently of high grade
that are consistentwith acute GVHD. Remarkably, once again,
all cases of diarrhea resolved, but this time upon treatment
with corticosteroids. Thus, the authors conclude that late
colitis did not present with histologic ﬁndings consistent
with CCS and was most consistent with acute GVHD.
There are several distinct features to this study when
compared with the initial report that diminish our ability to
draw ﬁrm conclusions. First, the Seattle cohort was younger,
utilized more myeloablative conditioning, employed
different immune prophylaxis, and more frequently experi-
enced gastrointestinal GVHD early after UBCT. As a result,
40% of Seattle patients versus 9% of Boston patients were
taking corticosteroids at the onset of diarrhea. Therefore, it is
certainly plausible that these factors greatly contributed to
the discordant histologic ﬁndings. Second, we do not know
whether patients in the Seattle cohort would have been
responsive to antibiotics or vice versa. Third, the authors did
not perform analyses for infectious agents, particularly for
the presence of B. enterica [7]. Lastly, the authors point out
the results may be a consequence of local-regional enteric
pathogens and effects of microbiota. However, despite these
distinctions, an important similarity was that most patients
in both series exhibited histologic evidence of apoptosis to
varying degrees. Because GVHD is the principle complication
after allogeneic transplantations and apoptosis is the sine
qua non histologic criterion of GVHD, the conclusions of
Milano et al. should be thoughtfully considered.
Despite great advances in molecular techniques, the
diagnosis of GVHD remains clinical. It is important to remind
ourselves that it took years before GVHD was well described
as a clinical entity. Even then, pathologic deﬁnitions of
apoptosis were introduced over 30 years ago to provide
objective evidence of the diagnosis [10]. The advent of both
reduced-intensity conditioning and alternative donor sour-
ces has been associated with the emergence of newly
described entities, such as late-onset acute GVHD and over-
lap syndrome [11]. In light of the ﬁndings of Milano et al., CCS
could alternatively be explained as a variant of GVHD unique
to the UBCT setting. At least ostensibly, this would notexplain the response of CCS to antibiotics. However, the
combination of metronidazole and ciproﬂoxacin has been
shown to prevent GVHD in matched related donors [12].
Furthermore, metronidazole has modest activity in chronic
inﬂammatory conditions of the bowel, such as Crohn’s dis-
ease [13,14]. Thus, metronidazole could possess immuno-
modulatory properties sufﬁcient to curtail mild forms of
GVHD. Alternatively, CCS could be a variant of GVHD that is
precipitated by B. enterica in patients after UBCT.
This work raises questions regarding the presence and
deﬁning features of CCS. Although both series were per-
formed at high-volume transplantation centers, cases
numbers of late onset watery diarrhea were very small,
suggesting that amulticenter effort with rigorous sequencing
efforts would be needed to further evaluate CCS. Additional
corroborationwith biomarkers could conceivably distinguish
CCS from GVHD. Better diagnosis could have signiﬁcant
clinical ramiﬁcations, including whether to treat with corti-
costeroids or antibiotics. Because immunosuppression re-
mains the standard for GVHD but has serious downsides, and
considering the uncertainty in the diagnosis of CCS, patients
with late-onset UBCT diarrhea require close follow-up for
signs of progression after treatment with either modality.
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